GlassScriptPhysician profile
Shamel Sanani
NPI 1174522585
$2,691.45
in general payments reported to CMS, 2019-2025
31 companies · $47.78 in 2025
The $47.78 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,748 · 2020: $424 · 2021: $76.05 · 2022: $252 · 2023: $144 · 2025: $47.78.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $161 · Education: $30.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $161.20 |
| Education | $30.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $411.61 | 2019-2022 | |
| Pfizer INC. | $253.67 | 2019-2025 | |
| Genzyme Corporation | $190.80 | 2019-2020 | |
| Janssen Biotech, INC. | $177.25 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $165.27 | 2019-2021 | |
| Jazz Pharmaceuticals INC. | $144.07 | 2023 | |
| Genentech USA, INC. | $126.24 | 2019-2020 | |
| Amgen INC. | $112.31 | 2019-2020 | |
| Pharmacyclics LLC, An Abbvie Company | $97.15 | 2019-2020 | |
| Beigene USA, INC. | $95.41 | 2022 | |
| Astellas Pharma US INC | $91.07 | 2019 | |
| Novartis Pharmaceuticals Corporation | $89.18 | 2019-2020 | |
| Seagen INC. | $78.62 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $77.80 | 2019 | |
| Glaxosmithkline, LLC. | $72.68 | 2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Array Biopharma INC | $66.87 | 2019 | |
| Incyte Corporation | $63.14 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $55.35 | 2019-2020 | |
| Eisai INC. | $47.04 | 2019-2020 | |
| Clovis Oncology, INC. | $38.48 | 2019 | |
| Puma Biotechnology, INC. | $37.16 | 2019 | |
| Sirtex Medical INC | $28.18 | 2019 | |
| Foundation Medicine, INC. | $26.97 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $25.00 | 2019 | |
| Tesaro, INC. | $24.64 | 2019 | |
| Alexion Pharmaceuticals, INC. | $19.76 | 2019 | |
| Gilead Sciences, INC. | $19.32 | 2019 | |
| Btg International INC. | $17.29 | 2019 | |
| Lilly USA, LLC | $14.90 | 2021 | |
| Kite Pharma, INC. | $12.22 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shamel Sanani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.